Anapafseos 5 . Agios Nikolaos
Crete.Greece.72100
2841026182
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,
Publication date: September 2017
Source:Chemosphere, Volume 182
Author(s): Xian Zhou, Min Zhou, Xian Wu, Yi Han, Junjun Geng, Teng Wang, Sha Wan, Haobo Hou
Fly ash is a hazardous byproduct of municipal solid waste incineration (MSWI). Cementitious material that is based on ground-granulated blast furnace slag (GGBFS) has been tested and proposed as a binder to stabilize Pb, Cd, and Zn in MSWI fly ash (FA). Cr, however, still easily leaches from MSWI FA.Different reagents, such as ascorbic acid (VC), NaAlO2, and trisodium salt nonahydrate, were investigated as potential Cr stabilizers. The results of the toxicity characteristic leaching procedure (TCLP) showed that VC significantly improved the stabilization of Cr via the reduction of Cr(VI) to Cr(III). VC, however, could interfere with the hydration process. Most available Cr was transformed into stable Cr forms at the optimum VC content of 2 wt%. Cr leaching was strongly pH dependent and could be represented by a quintic polynomial model. The results of X-ray diffraction and scanning electron microscopy-energy dispersive analysis revealed that hollow spheres in raw FA were partially filled with hydration products, resulting in the dense and homogeneous microstructure of the solidified samples. The crystal structures of C–S–H and ettringite retained Zn and Cr ions. In summary, GGBFS-based cementitious material with the low addition of 2 wt% VC effectively immobilizes Cr-bearing MSWI FA.
Next-generation sequencing technologies have enabled the comprehensive characterization of human and mouse genomes, including at the transcriptional level. This article reviews the degree of conservation of human and mouse transcriptomes, along with the challenges of identifying when the mouse is a suitable model of human physiology.
http://ift.tt/2qR49sE
Three-dimensional genome organization can shape gene expression by facilitating interactions between regulatory elements. The authors review the process of X-chromosome inactivation with a focus on chromatin organization and subnuclear localization of the active and inactive X chromosomes, as well as the potential roles of long non-coding RNAs.
http://ift.tt/2qfRsuD
Multicellular organisms rely on a complex interplay between diverse cell types, but how multicellularity evolved from unicellular ancestors has long been a debated research question. In this Review, the authors describe how comparative and functional genomics have provided valuable insights into the transition between unicellularity and multicellularity, including how various molecular networks have been adopted for multicellular life.
http://ift.tt/2qR0ye2
Publication date: July 2017
Source:Biomedicine & Pharmacotherapy, Volume 91
Author(s): Mojgan Esparvarinha, Hamid Nickho, Hamed Mohammadi, Leili Aghebati-Maleki, Jalal Abdolalizadeh, Jafar Majidi
Kappa (κ) or lambda (λ) free light chains (FLCs) are produced from B cells during immunoglobulin synthesis. FLCs have been shown to participate in several key processes of immune responses. They are necessary to adjust PMN functions and assist PMN pre-stimulation. Moreover, they cause mast cell degranulation which releases pro-inflammatory mediators and stimulates local inflammatory responses in some conditions such as inflammatory bowel disease (IBD). Having low molecular weights which may straightly be toxic to proximal tubule cells (PTCs), FLCs can also have an important role in renal diseases. In this review we have highlighted the involvement of light chains in the pathogenesis of some inflammatory diseases and discussed their potential to be the targets of therapeutic purposes.
http://ift.tt/2qR7V4I
Dangling regimes after free flap surgery to the lower limb vary between centres and clinicians. There is currently no accepted gold standard. This review examines the evidence for early versus late post-operative dangling after free flap reconstruction of the lower limb. The secondary aim is to evaluate the regimes used.
http://ift.tt/2paQdfV
Publication date: Available online 6 May 2017
Source:European Journal of Surgical Oncology (EJSO)
Author(s): Jennifer A. Flemming, Sulaiman Nanji, Xuejiao Wei, Colleen Webber, Patti Groome, Christopher M. Booth
Factors associated with time-to-surgery (TTS) and survival in colon cancer has not been well studied. Cancer Care Ontario recommends surgery within 42 days of diagnosis and that 90% of patients meet this benchmark. We describe factors associated with TTS and survival in routine clinical practice. Methods: Retrospective population-based cohort study of patients receiving elective colonic resection after diagnosis of colon cancer in Ontario, Canada from 2002-2008 followed until 2012. Factors associated with TTS were identified using multivariate log-binomial and Quantile regression at 42 days and 90th percentiles. The association between TTS and cancer-specific (CSS) and overall survival (OS) were examined using multivariate Cox regression. Results: 4,326 patients; median age 71 years and 52% male. Median TTS was 24 days (IQR 14-37); at the 90th percentile 56 days. Factors associated with TTS ≥ 42 days and > 90th percentile included older age, co-morbid illness, surgeon volume, and stage I disease (P < 0.05 for all). In patients whose TTS was either at 42 days or 90th percentile, those ≥ 80 years old waited two weeks longer than those < 60 years, individuals with co-morbid illness waited 10 days longer than without co-morbidity, and patients with stage I disease waited 10 days longer than those with stage IV disease (P < 0.05 for all). Delay in TTS > 42 days or > 90th percentile was not associated with OS or CSS. Conclusion: Age, co-morbidity, and stage of cancer are associated with TTS. There was no association between TTS and CSS or OS.
http://ift.tt/2poLIdN
Publication date: Available online 6 May 2017
Source:Peptides
Author(s): Simon Ingves, Nathalie Vilhelmsson, Edvin Ström, Mats Fredrikson, Hans Guldbrand, Fredrik H. Nystrom
ObjectiveLittle is known about human postprandial increase of energy expenditure and satiety-associated hormones in relation to both meal frequency and macronutrient composition.DesignRandomized cross-over study with four conditions for each participant.MethodsSeven men and seven women (mean age 23±1.5years) were randomly assigned to the order of intake of a 750kcal drink with the same protein content while having either 20 energy-percent (E%) or 55 E% from carbohydrates and the remaining energy from fat. Participants were also randomized to consume the drinks as one large beverage or as five 150kcal portions every 30minutes, starting in the fasting state in the morning. Energy expenditure (EE) was determined every 30minutes by indirect calorimetry. Hormonal responses and suppression of hunger (by visual-analogue scales) were also studied. A p<0.013 was considered statistically significant following Bonferroni-correction.ResultsThe area under the curve (AUC) for EE was higher during the 2.5hours after the high-carbohydrate drinks (p=0.005 by Wilcoxon) and also after ingesting one drink compared with five (p=0.004). AUC for serum active GLP-1 was higher after single drinks compared with five beverages (p=0.002). Although GLP-1 levels remained particularly high at the end of the test during the low-carbohydrate meals, the AUC did not differ compared with the high-carbohydrate occasions (low-carbohydrate: 58.9±18pg/ml/h, high-carbohydrate: 45.2±16pg/ml/h, p=0.028). Hunger sensations were suppressed more after single beverages compared with five small drinks (p=0.009).ConclusionsWe found higher EE during 2.5hours following one large drink compared with five smaller beverages. Since hunger was also suppressed more efficiently, and serum GLP-1 levels were higher after one compared with five smaller drinks, our findings do not support nibbling to avoid hunger or to keep up EE from morning to noon.
http://ift.tt/2pQcYo2
Publication date: Available online 7 May 2017
Source:European Journal of Vascular and Endovascular Surgery
Author(s): G. Simonte, G. Parlani, L. Farchioni, G. Isernia, E. Cieri, M. Lenti, P. Cao, F. Verzini
Objective/BackgroundAbsence of an adequate iliac seal rarely represents an absolute contraindication to endovascular abdominal aortic aneurysm repair. Iliac branch devices (IBD) are increasingly used in patients with extensive aorto-iliac aneurysmal disease, but few data are available on the long-term results of these procedures.MethodsBetween 2006 and 2016, 157 consecutive IBD procedures performed at a single centre were entered into a prospective database. Indications included unilateral or bilateral common iliac artery aneurysms combined or not with abdominal aortic aneurysms. Long-term results were reported according to the Kaplan–Meier method.ResultsDuring the study period 149 patients were treated with an iliac branched endograft. Isolated IBD was implanted in 17.8% of the cases; technical success rate was 97.5%. Peri-operative procedure failure occurred in seven patients, four during surgery and three within 30 days of the procedure. Presence of ipsilateral hypogastric aneurysm (p = .031; Exp [B] = 6.72) and intervention performed during the initial study period (p = .006; Exp [B] = 10.40) were predictive of early failure on multivariate analysis. After a mean follow-up of 44.2 months actuarial freedom from IBD related re-intervention was 97.4%, 95.6%, 94.0%, and 91.8% at 1, 3, 5, and 9 years, respectively. Hypogastric artery patency was 94.7%, 92.6%, and 90.4% at 1, 3, and 10 years, respectively. Presence of a hypogastric aneurysm was an independent predictor of target artery occlusion during follow-up on multivariate analysis (p = .007; Exp [B] = 5.93).ConclusionIliac branched endografting can now be performed with a high technical success rate; long-term freedom from re-intervention is comparable with patients treated with standard aortic endografting. IBD should be considered a first-option treatment in patients with adequate vascular anatomy unsuitable for standard endovascular aortic repair.
http://ift.tt/2pTZMir
Publication date: Available online 7 May 2017
Source:European Journal of Vascular and Endovascular Surgery
Author(s): S. Regus, W. Lang
http://ift.tt/2pVjmZU
Publication date: May–June 2017
Source:Brachytherapy, Volume 16, Issue 3, Supplement
Author(s): William J. Morris, Mira Keyes, Tom Pickles
http://ift.tt/2pjHcMW
Publication date: May–June 2017
Source:Brachytherapy, Volume 16, Issue 3, Supplement
Author(s): Nichole M. Maughan, Jose Garcia-Ramirez, Matt Arpidone, Amy Swallen, Richard Laforest, S. Murty Goddu, Parag J. Parikh, Jacqueline E. Zoberi
http://ift.tt/2pjKEHe
Publication date: May–June 2017
Source:Brachytherapy, Volume 16, Issue 3, Supplement
http://ift.tt/2qG40uO
Publication date: May–June 2017
Source:Brachytherapy, Volume 16, Issue 3, Supplement
Author(s): Vinayak Muralidhar, Peter F. Orio, Paul L. Nguyen, Ivan Buzurovic, Neil E. Martin, Phillip M. Devlin, Martin T. King
http://ift.tt/2pjGMGo
Publication date: May–June 2017
Source:Brachytherapy, Volume 16, Issue 3, Supplement
http://ift.tt/2pjZZYx
Publication date: May–June 2017
Source:Brachytherapy, Volume 16, Issue 3, Supplement
Author(s): Adam D. Bastien, Ileana N. Iftimia, Per H. Halvorsen, Mark J. Rivard
http://ift.tt/2qGlhV0
Publication date: May–June 2017
Source:Brachytherapy, Volume 16, Issue 3, Supplement
http://ift.tt/2pjW6mk
Publication date: May–June 2017
Source:Brachytherapy, Volume 16, Issue 3, Supplement
Author(s): John V. Hegde, D. Jeffrey Demanes, Darlene Veruttipong, Jagdeep Raince, Sang-June Park, Mitchell Kamrava
http://ift.tt/2qGa4Uf
Publication date: May–June 2017
Source:Brachytherapy, Volume 16, Issue 3, Supplement
Author(s): Gerard Morton, Hans Chung, Merrylee McGuffin, Ananth Ravi, Stanley Liu, Eric Tseng, Liying Zhang, Andrew Loblaw
http://ift.tt/2pjQWa5
Publication date: May–June 2017
Source:Brachytherapy, Volume 16, Issue 3, Supplement
http://ift.tt/2qFXSTj
Publication date: May–June 2017
Source:Brachytherapy, Volume 16, Issue 3, Supplement
Author(s): Karen Episcopia, Gil'ad N. Cohen, Christopher Crane, Amandeep S. Taggar, Abraham J. Wu, Antonio L. Damato
http://ift.tt/2pjV4Xx
Publication date: May–June 2017
Source:Brachytherapy, Volume 16, Issue 3, Supplement
Author(s): Gabriel Famulari, John J. Munro, Shirin Abbasinejad Enger
http://ift.tt/2qGpZBT
Publication date: May–June 2017
Source:Brachytherapy, Volume 16, Issue 3, Supplement
Author(s): Gabriel Famulari, Shirin Abbasinejad Enger
http://ift.tt/2pjQYyB
Publication date: May–June 2017
Source:Brachytherapy, Volume 16, Issue 3, Supplement
Author(s): Chengli Li
http://ift.tt/2qGpYhj
Publication date: May–June 2017
Source:Brachytherapy, Volume 16, Issue 3, Supplement
Author(s): Uzoma K. Iheagwara, Danielle Burton, John A. Vargo, Michelle M. Boisen, John T. Comerci, HaYeon Kim, Christopher J. Houser, Paniti Sukumvanich, Alexander B. Olawaiye, Joseph L. Kelley, Robert P. Edwards, Madeleine Courtney-Brooks, Jessica L. Berger, Sarah E. Taylor, Sushil Beriwal
http://ift.tt/2pjVb5p
Publication date: May–June 2017
Source:Brachytherapy, Volume 16, Issue 3, Supplement
Author(s): Chenyang Wang, Jagdeep Raince, Sang-June Park, Shane Mesko, Jeffrey Demanes, Mitchell Kamrava
http://ift.tt/2qFScsG
Publication date: May–June 2017
Source:Brachytherapy, Volume 16, Issue 3, Supplement
Author(s): Bridget A. Quinn, Xiaoyan Deng, Adrianne Colton, Dipankar Bandyopadhyay, Jori Carter, Emma Fields
http://ift.tt/2pjVa1l
Publication date: Available online 6 May 2017
Source:Pathology - Research and Practice
Author(s): Juliane Büttner, Annika Lehmann, Frederick Klauschen, Michael Hummel, Dido Lenze, Manfred Dietel, Korinna Jöhrens
Evaluation of the RAS mutation status is necessary for patients with advanced colorectal cancer to predict the response to anti-EGFR therapy. In routine diagnostics, FFPE tissue samples are tested by sequencing (amplicon-based NGS and Sanger) to obtain the RAS status of the patient. Samples that are collected after chemotherapy occasionally contain necrotic tissue. Furthermore, colorectal cancer tissue sometimes has mucinous components. This may pose a challenge to molecular analysis because mucinous tumor samples often contain only few tumor cells compared to solid tumor samples. Therefore, the aim of this study was to explore if mucin or necrosis affect mutation analysis and if mucinous tumor samples contain enough tumor cells for reliable mutation detection. To this end, we analyzed KRAS status in 10 samples showing mucin production and 10 samples with necrosis. In all 20 samples the tissue areas with the highest amount of mucin or necrosis were used for re-evaluation. These results show no differences with those obtained during routine diagnostics, where analysis of mucinous or necrotic areas was tried to avoid. Our study thus shows that mucin and necrosis have no influence on KRAS mutation analysis. Furthermore we were able to demonstrate that mucinous adenocarcinoma contains enough tumor cells for a valid mutation analysis. In addition, we also observed only minor differences in KRAS status results when comparing Sanger sequencing with NGS. Both methods detected the KRAS mutation in 19 of 20 tested samples, even for mutated samples with low allele-frequencies.
http://ift.tt/2pa7eXC
Publication date: Available online 6 May 2017
Source:Pathology - Research and Practice
Author(s): D. Cortés-Guiral, C. Pastor-Iodate, C. Díaz del Arco, L. del Puerto-Nevado, M.J. Fernández-Aceñero
The cytoplasmic polyadenylation element binding protein 4 (CPEB4) is a RNA binding protein and translational regulator. It has been associated with tumor growth, vascularization and invasion and with tumor progression in breast, pancreas and lung carcinomas. To the best of our knowledge only one previous report has analyzed the prognostic value of CPEB4 in an experimental model of colorectal carcinoma. We have reviewed the files of patients with stage IV colorectal carcinoma metastatic to the liver. All the patients had received chemotherapy followed by hepatic metastasis resection and subsequent resection of the colon (liver-first approach). We have gathered demographic, analytical and morphological data of the primary tumors. We have performed immunohistochemical analysis of CPEB4 expression in these tumors and analyzed the potential prognostic value of this protein. 50 patients fulfilled inclusion criteria for the present study. All of them received preoperative chemotherapy based on platinum and also postoperative chemotherapy, with or without targeted drugs (18% received anti-epidermal growth factor receptor (EGFR) drugs and 24% anti-vascular endothelial growth factor receptor (VEGFR) drugs. 66% of the primaries were of sigmoid-rectal origin. CPEB4 expression was mainly cytoplasmic and it was scored as intense in 46% of the patients. Survival analysis revealed a significant association between progression free survival (PFS) and overall survival (OS) and CPEB4 immunohistochemical expression, which was independent in the multivariate analysis.CPEB4 behaves as a significant predictor of prognosis in stage IV colorectal carcinoma. The existence of CPEB4 specific inhibitors can open a new way for targeted therapy. Larger prospective studies are needed to confirm our promising results.
http://ift.tt/2pUOEjm
Publication date: Available online 6 May 2017
Source:Pathology - Research and Practice
Author(s): Mozhdeh Foroozan, Raheleh Roudi, Maryam Abolhasani, Elmira Gheytanchi, Mitra Mehrazma
Prostate cancer is the second cause of cancer-related deaths in men and this is attributed to its aggressiveness and metastatic identity. Our objective was to evaluate the expression patterns of endothelial cell marker CD34 and mast cell marker CD117 in prostate adenocarcinoma (PCa) compared to benign prostate tissue and their relation to the clinicopathological features. A total of 90 prostate samples, including 45 PCa and 45 benign prostate tissues were immunohistochemically examined for the detection of CD34 and CD117 markers. The expression of these markers was also correlated with clinicopathological parameters. Significant overexpression of CD34 was found in PCa group compared to benign prostate tissues (P≤0.001). The expression of CD34 and CD117 in PCa with advanced Gleason score was more than PCa with early Gleason score (P=0.02 and P=0.005, respectively). A significant positive correlation was observed between CD34 expression and the level of total serum prostate specific antigen (sPSA) (P=0.006). In addition, CD34High/CD117High phenotype was frequently observed in PCa cases compared to benign prostate tissues (P≤0.001). There was a positive significant association between CD34High/CD117High phenotype with advanced Gleason score (P≤0.001) and total sPSA level (P=0.02). Our findings showed that increased expression of CD34 and CD117 markers confer tumor progression and aggressiveness on PCa. These molecules may be good candidates for targeted therapy of PCa patients.
http://ift.tt/2p9W98V
Publication date: Available online 6 May 2017
Source:Pathology - Research and Practice
Author(s): M. Gambarotti, A. Righi, T. Frisoni, D. Donati, D. Vanel, M. Sbaraglia, A.P. Dei Tos
Dedifferentiated chondrosarcoma is defined by the presence of a low grade malignant cartilaginous component juxtaposed to a high grade malignant non-cartilaginous sarcomatous components. Only 4 cases in which the high grade component showed epithelial differentiation have been reported in the literature; three featured a squamous and the one a glandular epithelial component. Here we describe a case of dedifferentiated chondrosarcoma exhibiting epithelial "adamantinoma-like" basaloid features. The patient underwent wide resection of the proximal tibia and post-operative chemotherapy and died 8 months after the diagnosis due to lung and bone metastases.
http://ift.tt/2pUZHcc
Publication date: Available online 6 May 2017
Source:Journal of Dermatological Science
Author(s): ChunSik Choe, Johannes Schleusener, Jürgen Lademann, Maxim E. Darvin
BackgroundThe intercellular lipids (ICL) of stratum corneum (SC) play an important role in maintaining the skin barrier function. The lateral and lamellar packing order of ICL in SC is not homogenous, but rather depth-dependent.ObjectiveThis study aimed to analyze the influence of the topically applied mineral-derived (paraffin and petrolatum) and plant-derived (almond oil and jojoba oil) oils on the depth-dependent ICL profile ordering of the SC in vivo.MethodConfocal Raman microscopy (CRM), a unique tool to analyze the depth profile of the ICL structure non-invasively, is employed to investigate the interaction between oils and human SC in vivo.ResultsThe results show that the response of SC to oils' permeation varies in the depths. All oils remain in the upper layers of the SC (0–20% of SC thickness) and show predominated differences of ICL ordering from intact skin. In these depths, skin treated with plant-derived oils shows more disordered lateral and lamellar packing order of ICL than intact skin (p<0.05). In the intermediate layers of SC (30–50% of SC thickness), the oils do not influence the lateral packing order of SC ICL (p>0.1), except plant-derived oils at the depth 30% of SC thickness. In the deeper layers of the SC (60–100% of SC thickness), no difference between ICL lateral packing order of the oil-treated and intact skin can be observed, except that at the depths of 70–90% of the SC thickness, where slight changes with more disorder states are measured for plant-derived oil treated skin (p<0.1), which could be explained by the penetration of free fatty acid fractions in the deep-located SC areas.ConclusionBoth oil types remain in the superficial layers of the SC (0–20% of the SC thickness). Skin treated with mineral- and plant-derived oils shows significantly higher disordered lateral and lamellar packing order of ICL in these layers of the SC compared to intact skin. Plant-derived oils significantly changed the ICL ordering in the depths of 30% and 70–90% of the SC thickness, which is likely due to the penetration of free fatty acids in the deeper layers of the SC.
http://ift.tt/2qP59h0
Publication date: Available online 6 May 2017
Source:Clinical Imaging
Author(s): Yan Epelboym, Abhishek R. Keraliya, Sree Harsha Tirumani, Jason L. Hornick, Nikhil H. Ramaiya, Atul B. Shinagare
PurposeCompare imaging features of indolent and non-indolent mastocytosis.MethodsFor 29 patients, imaging features, imaging indications, and distribution of indolent and non-indolent mastocytosis subtypes were analyzed.Results16/29 (55%) patients had three distinct patterns of osseous abnormality, not significantly differing between cohorts. Non-indolent disease was more likely to present with hepatomegaly (p=0.0004), splenomegaly (p=0.0097), and lymphadenopathy (p=0.0079). CT, was the most common initial imaging modality, ordered to stage disease in 20 of 29 patients (69%).ConclusionUnderstanding patterns of involvement of indolent and nonindolent mastocytosis across modalities could assist radiologists in evaluating mastocytosis.
http://ift.tt/2pjvwtj
Publication date: June 2017
Source:Neoplasia, Volume 19, Issue 6
Author(s): Jim Moselhy, Suman Suman, Mohammed Alghamdi, Balaji Chandarasekharan, Trinath P Das, Alatassi Houda, Murali Ankem, Chendil Damodaran
We recently demonstrated that AKT activation plays a role in prostate cancer progression and inhibits the pro-apoptotic function of FOXO3a and Par-4. AKT inhibition and Par-4 induction suppressed prostate cancer progression in preclinical models. Here, we investigate the chemopreventive effect of the phytonutrient Withaferin A (WA) on AKT-driven prostate tumorigenesis in a Pten conditional knockout (Pten-KO) mouse model of prostate cancer. Oral WA treatment was carried out at two different doses (3 and 5 mg/kg) and compared to vehicle over 45 weeks. Oral administration of WA for 45 weeks effectively inhibited primary tumor growth in comparison to vehicle controls. Pathological analysis showed the complete absence of metastatic lesions in organs from WA-treated mice, whereas discrete metastasis to the lungs was observed in control tumors. Immunohistochemical analysis revealed the down-regulation of pAKT expression and epithelial-to-mesenchymal transition markers, such as β-catenin and N-cadherin, in WA-treated tumors in comparison to controls. This result corroborates our previous findings from both cell culture and xenograft models of prostate cancer. Our findings demonstrate that the daily administration of a phytonutrient that targets AKT activation provides a safe and effective treatment for prostate cancer in a mouse model with strong potential for translation to human disease.
http://ift.tt/2qdmof3